This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain. IBRANCE® (palbociclib) Prescribing Information for Great Britain click here. IBRANCE® (palbociclib) Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

PALOMA-2 Trial

Confidence In A Treatment that’s Setting The Standard1-2

Primary results from a Phase III trial of IBRANCE® plus letrozole compared with placebo plus letrozole in post-menopausal women with endocrine receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) locally advanced and metastatic breast cancer.1,2​​​​​​​​​​​​​​

Study Design

Study design and patient populations for the phase III PALOMA-2 Trial

View

Efficacy Outcomes

Efficacy outcomes including mPFS, tumour response rates and delay to chemotherapy​​​​​​​

View

Quality of Life Outcomes

FACT-B Quality of Life outcomes​​​​​​​

View

Safety Profile

IBRANCE® safety and frequently reported adverse events

View

IBRANCE® Mode of Action

Dual inhibition with endocrine therapy

View

IBRANCE® Real World Evidence

Real-world evidence for IBRANCE® (palbociclib) in advanced Breast Cancer

Read more

AI : Aromatase Inhibitor, ER+ : Oestrogen Receptor-positive, ET : Endocrine Therapy, HER2- : Human Epidermal growth factor Receptor 2-negative, HR+ : Hormone Receptor-positive, LHRH : Luteinising Hormone-Releasing Hormone, mBC :  metastatic Breast Cancer

 ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

References
  1. Rugo HS, et al. Breast Cancer Res Treat. 2019;174:719–29.
  2. Finn RS, et al. N Engl J Med. 2016;375:1925-1936.
PP-IBR-GBR-3744. July 2021

PALOMA-2 Trial

IBRANCE® + Aromatase Inhibitor (AI) Clinical Trial Results

  • Study Design
  • Efficacy Outcomes
  • Quality of Life Outcomes
  • Safety Profile
  • IBRANCE® Mode of Action

Efficacy

Efficacy results for IBRANCE®

  • IBRANCE® Efficacy

Safety

IBRANCE® safety information and outcomes

  • IBRANCE® Safety Profile
  • Neutropenia
  • Adverse Event Management

Indication

  • IBRANCE® is indicated for the treatment of HR+ HER2- locally advanced or metastatic breast cancer:
       - In combination with an aromatase inhibitor; or
    ​​​​​​​   - In combination with fulvestrant in women who have received prior ET

    In pre- or perimenopausal women, the ET should be combined with a LHRH agonist

Ask Pfizer

Connect virtually with a Pfizer representative to discuss promotional information on a selected range of products.

Book now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No